Literature DB >> 30656382

[Angioedema prophylaxis].

V Zampeli1, M Magerl2.   

Abstract

Angioedema is a spontaneous, edematous swelling of the deep layers of the skin or mucous membrane. Angioedema in the respiratory tract is potentially life-threatening. The classification of angioedema into mast-cell-mediated (e. g. urticaria) or bradykinin-mediated (e. g. hereditary angioedema) is important for correct and rational treatment. Generally, two therapeutic strategies are available for angioedema treatment. On-demand treatment of angioedema symptoms that already have emerged aims to stop the further development of the attack and, thus, limits the severity and duration of the attack. This strategy is well established in the treatment of patients with hereditary angioedema, whereas in chronic spontaneous urticaria on-demand therapy plays no role in the guideline recommendations. In contrast, the therapeutic strategy of prophylaxis aims to prevent the occurrence of spontaneous and induced attacks as far as possible. Prophylaxis is the sole therapy strategy for chronic urticaria and is applied at all stages of the treatment algorithm. In the case of hereditary angioedema, on-demand therapy can be complemented by prophylaxis after careful and individual indication. In hereditary angioedema, prophylaxis is currently gaining in importance due to improved treatment options. Patients who use a prophylactic regime are much less likely to be forced to wait for the unpredictable occurrence of an attack and then to react with an on-demand treatment. Prophylactic treatment takes place at times determined by the patient himself, in contrast to treatment on an as-needed basis. The loss of unpredictability is a decisive moment in improving the quality of life.

Entities:  

Keywords:  C1-Inhibitor deficiency; Chronic spontaneous urticaria; Long-term prophylaxis; On-demand therapy; Short-term prophylaxis

Mesh:

Substances:

Year:  2019        PMID: 30656382     DOI: 10.1007/s00105-018-4345-9

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  33 in total

1.  Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant.

Authors:  K Weller; M Magerl; M Maurer
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-01       Impact factor: 6.166

2.  Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema.

Authors:  Julián Azofra; Carmen Díaz; Ignacio Antépara; Ignacio Jaúregui; Ana Soriano; Marta Ferrer
Journal:  Ann Allergy Asthma Immunol       Date:  2015-03-04       Impact factor: 6.347

3.  Type III hereditary angio-oedema: clinical and biological features in a French cohort.

Authors:  V Vitrat-Hincky; A Gompel; C Dumestre-Perard; I Boccon-Gibod; C Drouet; J Y Cesbron; J Lunardi; C Massot; L Bouillet
Journal:  Allergy       Date:  2010-04-07       Impact factor: 13.146

4.  Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.

Authors:  Hilary Longhurst; Marco Cicardi; Timothy Craig; Konrad Bork; Clive Grattan; James Baker; Huamin H Li; Avner Reshef; James Bonner; Jonathan A Bernstein; John Anderson; William R Lumry; Henriette Farkas; Constance H Katelaris; Gordon L Sussman; Joshua Jacobs; Marc Riedl; Michael E Manning; Jacques Hebert; Paul K Keith; Shmuel Kivity; Sergio Neri; Donald S Levy; Maria L Baeza; Robert Nathan; Lawrence B Schwartz; Teresa Caballero; William Yang; Ioana Crisan; María D Hernandez; Iftikhar Hussain; Michael Tarzi; Bruce Ritchie; Pavlina Králíčková; Mar Guilarte; Syed M Rehman; Aleena Banerji; Richard G Gower; Debra Bensen-Kennedy; Jonathan Edelman; Henrike Feuersenger; John-Philip Lawo; Thomas Machnig; Dipti Pawaskar; Ingo Pragst; Bruce L Zuraw
Journal:  N Engl J Med       Date:  2017-03-23       Impact factor: 91.245

5.  Pathogen safety of human C1 esterase inhibitor concentrate.

Authors:  Albrecht Gröner; Thomas Nowak; Wolfram Schäfer
Journal:  Transfusion       Date:  2012-03-13       Impact factor: 3.157

6.  HAE international home therapy consensus document.

Authors:  Hilary J Longhurst; Henriette Farkas; Timothy Craig; Emel Aygören-Pürsün; Claire Bethune; Janne Bjorkander; Konrad Bork; Laurence Bouillet; Henrik Boysen; Anette Bygum; Teresa Caballero; Marco Cicardi; John Dempster; Mark Gompels; Jimmy Gooi; Sofia Grigoriadou; Ursula Huffer; Wolfhart Kreuz; Marcel M Levi; Janet Long; Inmaculada Martinez-Saguer; Michel Raguet; Avner Reshef; Tom Bowen; Bruce Zuraw
Journal:  Allergy Asthma Clin Immunol       Date:  2010-07-28       Impact factor: 3.406

Review 7.  Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency.

Authors:  Jens Greve; Ulrich Strassen; Marina Gorczyza; Nina Dominas; Uta-Marie Frahm; Heike Mühlberg; Michaela Wiednig; Vasiliki Zampeli; Markus Magerl
Journal:  J Dtsch Dermatol Ges       Date:  2016-03       Impact factor: 5.584

8.  Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy.

Authors:  Konrad Bork; Karin Wulff; Jochen Hardt; Günther Witzke; Petra Staubach
Journal:  J Allergy Clin Immunol       Date:  2009-05-27       Impact factor: 10.793

9.  Acquired angioedema--occurrence, clinical features and associated disorders in a Danish nationwide patient cohort.

Authors:  Anette Bygum; Hanne Vestergaard
Journal:  Int Arch Allergy Immunol       Date:  2013-07-31       Impact factor: 2.749

10.  Omalizumab for Idiopathic Nonhistaminergic Angioedema: Evidence for Efficacy in 2 Patients.

Authors:  Enrico Brunetta; Dana Shiffer; Marco Folci; Maria I S Achenza; Francesca Puggioni; Enrico Heffler; Raffaello Furlan; Giorgio W Canonica
Journal:  Case Reports Immunol       Date:  2018-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.